The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials. Patients and Methods: KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care (BSC). We tested whether the effect of panitumumab on progression-free survival (PFS) differed by KRAS status. Results: KRAS status was ascertained in 427 (92%) of 463 patients (208 panitumumab, 219 BSC). KRAS mutations were found in 43% of patients. The treatment effect on PFS in the wild-type (WT) KRAS group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P < .0001) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3 weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and 0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival (HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined). Consistent with longer exposure, more grade III treatment-related toxicities occurred in the WT KRAS group. No significant differences in toxicity were observed between the WT KRAS group and the overall population. Conclusion: Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors. KRAS status should be considered in selecting patients with mCRC as candidates for panitumumab monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux®) in metastatic colorectal cancer (mCRC).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Amado et al., 2008
Experimental — accuracy not yet measuredIn the citing paper
“Patients must have KRAS wt tumors for panitumumab to be effective [22,23].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [22]
In the citing paper
“Although exclusion of patients with KRAS (exon 2)-mutant tumors has arithmetically increased the percentage of responders up to 13–17 %”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [32]
In the citing paper
“most KRAS wild-type tumors still do not respond to anti-EGFR moAbs [26, 32].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationMoore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
Newton, C. R., Graham, A., Heptinstall, L., Powell, S. J., Summers, C. W., Kalsheker, N. A., Smith, J. C., & Markham, A. F. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.7.2503 · Cited by 2,483
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,014
KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803
Ogino, S., Meyerhardt, J. A., Irahara, N., Niedzwiecki, D., Hollis, D. R., Saltz, L. B., Mayer, R. J., Schaefer, P., Whittom, R., Hantel, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1570 · Cited by 197
Chemotherapy for colorectal cancer in the elderly
Kim, J. H. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i17.5158 · Cited by 193
Intestinal stem cells in the adult Drosophila midgut
Jiang, H., & Edgar, B. A. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.07.020 · Cited by 198
Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy
Pines, G., Köstler, W. J., & Yarden, Y. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.019 · Cited by 199
Cancer Genomics: Technology, Discovery, and Translation
Tran, B., Dancey, J. E., Kamel‐Reid, S., McPherson, J. D., Bedard, P. L., Brown, A. M. K., Zhang, T., Shaw, P. H., Onetto-Pothier, N., Stein, L. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2316 · Cited by 188
EGFR Signaling in Colorectal Carcinoma
Krasinskas, A. M. (2011) · Pathology Research International · doi:10.4061/2011/932932 · Cited by 200
Tejpar, S., Bertagnolli, M. M., Bosman, F. T., Lenz, H.-J., Garraway, L. A., Waldman, F. M., Warren, R. S., Bild, A. H., Collins-Brennan, D., Hahn, H. P., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0233 · Cited by 189
Pietrantonio, F., Vernieri, C., Siravegna, G., Mennitto, A., Berenato, R., Perrone, F., Gloghini, A., Tamborini, E., Lonardi, S., Morano, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1863 · Cited by 182
BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon
Pai, R. K., Jayachandran, P., Koong, A. C., Chang, D. T., Kwok, S., Ma, L., Arber, D. A., Balise, R. R., Tubbs, R. R., Shadrach, B. L., et al. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31824430d7 · Cited by 182
Self-citationPeeters, M., Oliner, K. S., Price, T. J., Cervantes, A. M. R., Sobrero, A. F., Ducreux, M. P., Hotko, Y., André, T., Chan, E. W., Lordick, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0526 · Cited by 181
Self-citationS3-Leitlinie Kolorektales Karzinom Version 1.0 - Juni 2013 AWMF-Registernummer: 021/007OL
Pox, C. P., Aretz, S., Bischoff, S. C., Graeven, U., Hass, M., Heußner, P., Hohenberger, W., Holstege, A., Hübner, J., Kolligs, F. T., et al. (2013) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0033-1350264 · Cited by 181
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
Cappuzzo, F., Varella-Garcia, M., Finocchiaro, G., Skokan, M., Gajapathy, S., Carnaghi, C., Rimassa, L., Rossi, E., Ligorio, C., Di Tommaso, L., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604439 · Cited by 178
Rosfjord, E. C., Lucas, J., Li, G., & Gerber, H. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.06.008 · Cited by 178
Mohan, S., Heitzer, E., Ulz, P., Lafer, I., Lax, S., Auer, M., Pichler, M., Gerger, A., Eisner, F., Höefler, G., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004271 · Cited by 178
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine
Ogino, S., Fuchs, C. S., & Giovannucci, E. L. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.46 · Cited by 180
Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review
Tol, J., & Punt, C. J. A. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.03.012 · Cited by 178
Nash, G. M., Gimbel, M., Shia, J., Nathanson, D. R., Ndubuisi, M. I., Zeng, Z.-S., Kemeny, N., & Paty, P. B. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0605-3 · Cited by 172
Modjtahedi, H., & Essapen, S. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283330590 · Cited by 177
Pharmacogenetics in drug discovery and development: a translational perspective
Roses, A. D. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2593 · Cited by 177
Lordick, F., Luber, B., Lorenzen, S., Hegewisch-Becker, S., Folprecht, G., Wöll, E., Decker, T. W., Endlicher, E., Röthling, N., Schuster, T., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605521 · Cited by 176
Pragmatic issues in biomarker evaluation for targeted therapies in cancer
Gramont, A. D. E., Watson, S., Ellis, L. M., Rodon, J. A., Tabernero, J. M., de Gramont, A., & Hamilton, S. R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.202 · Cited by 179
A Personalized Approach to Cancer Treatment: How Biomarkers Can Help
Duffy, M. J., & Crown, J. P. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.110056 · Cited by 176
Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases
Chun, Y. S., Laurent, A., Maru, D. M., & Vauthey, J. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70064-6 · Cited by 171
Venook, A. P., Niedzwiecki, D., Lopatin, M., Ye, X., Lee, M., Friedman, P. N., Frankel, W. L., Clark-Langone, K. M., Millward, C. L., Shak, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1096 · Cited by 173
Mechanisms of action of therapeutic antibodies for cancer
Redman, J. M., Hill, E., Aldeghaither, D. S., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 179
Monoclonal antibodies for the treatment of cancer
Shuptrine, C. W., Surana, R., & Weiner, L. M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.009 · Cited by 177
Dahabreh, I. J., Terasawa, T., Castaldi, P. J., & Trikalinos, T. A. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-1-201101040-00006 · Cited by 174
Schirripa, M., Bergamo, F., Cremolini, C., Casagrande, M., Lonardi, S., Aprile, G., Yang, D., Marmorino, F., Pasquini, G., Sensi, E., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.142 · Cited by 170
The Use of Genomics in Clinical Trial Design
Simon, R. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4531 · Cited by 171
Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147
Gonsalves, W. I., Mahoney, M. R., Sargent, D. J., Nelson, G. D., Alberts, S. R., Sinicrope, F. A., Goldberg, R. M., Limburg, P. J., Thibodeau, S. N., Grothey, A. F., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju106 · Cited by 171
The Developing Story of Predictive Biomarkers in Colorectal Cancer
Boussios, S., Öztürk, M. A., Moschetta, M., Karathanasi, A., Zakynthinakis-Kyriakou, N., Katsanos, K. H., Christodoulou, D. K., & Pavlidis, N. A. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010012 · Cited by 172
Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?
Durães, C., Almeida, G. M., Seruca, R., Oliveíra, C., & Carneiro, F. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-013-1533-y · Cited by 171
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer
Schirripa, M., Cremolini, C., Loupakis, F., Morvillo, M., Bergamo, F., Zoratto, F., Salvatore, L., Antoniotti, C., Marmorino, F., Sensi, E., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28955 · Cited by 166
A Review of the Most Promising Biomarkers in Colorectal Cancer: One Step Closer to Targeted Therapy
Deschoolmeester, V., Baay, M. F. D., Specenier, P. M., Lardon, F., & Vermorken, J. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0025 · Cited by 172
The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
Eklöf, V., Wikberg, M. L., Edin, S., Dahlin, A. M., Jonsson, B.-A., Öberg, Å., Rutegård, M., & Palmqvist, R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.212 · Cited by 171
Squassina, A., Manchia, M., Manolopoulos, V. G., Artaç, M., Lappa-Manakou, C., Karkabouna, S., Mitropoulos, K. A., Zompo, M. D., & Patrinos, G. P. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.97 · Cited by 165
Peeters, M., Kafatos, G., Taylor, A., Gastanaga, V. M., Oliner, K. S., Hechmati, G., Terwey, J.-H., & van Krieken, J. H. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.017 · Cited by 163
Self-citationPersonalized Medicine: Marking a New Epoch in Cancer Patient Management
Diamandis, M., White, N. M. A., & Yousef, G. M. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0264 · Cited by 170
Freeman, D. J., Juan, T., Reiner, M. T., Hecht, J. R., Meropol, N. J., Berlin, J. D., Mitchell, E. P., Sarosi, I., Radinsky, R., & Amado, R. G. (2008) · Clinical Colorectal Cancer · doi:10.3816/ccc.2008.n.024 · Cited by 160
Self-citationKRAS and BRAF: drug targets and predictive biomarkers
Vakiani, E., & Solit, D. B. (2010) · The Journal of Pathology · doi:10.1002/path.2796 · Cited by 164
Metastatic Colon Cancer, Version 3.2013
Benson, A. B., Bekaii‐Saab, T., Chan, E. W., Chen, Y., Choti, M. A., Cooper, H. S., Engstrom, P. F., Enzinger, P. C., Fakih, M., Fenton, M. J., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0022 · Cited by 160
Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations
Wykosky, J., Fenton, T. R., Furnari, F. B., & Cavenee, W. K. (2011) · 癌症：英文版 · doi:10.5732/cjc.010.10542 · Cited by 158
Acquired resistance to EGFR‐targeted therapies in colorectal cancer
Emburgh, B. O. V., Bianchi, A. S., Nicolantonio, F. D., Siena, S., & Bardelli, A. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.003 · Cited by 162
Self-citationMolinari, F., Felicioni, L., Buscarino, M., De Dosso, S., Buttitta, F., Malatesta, S., Movilia, A., Luoni, M., Boldorini, R., Alabiso, O., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3137 · Cited by 159
Dillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 166
Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed
McLeod, H. L. (2013) · Science · doi:10.1126/science.1234139 · Cited by 156
Okita, A., Takahashi, S. I., Ouchi, K., Inoue, M., Watanabe, M., Endo, M., Honda, H., Yamada, Y., & Ishioka, C. (2018) · Oncotarget · doi:10.18632/oncotarget.24617 · Cited by 162
Loboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., Roberts, B., Zhang, T., Chenard, M., Haines, B., et al. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-26 · Cited by 152
Cejas, P., López-Gómez, M., Aguayo, C., Madero, R., de Castro, J., Belda-Iniesta, C., Barriuso, J., Moreno, V., Larrauri, J., López, R., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008199 · Cited by 154
Network quantification of EGFR signaling unveils potential for targeted combination therapy
Klinger, B., Sieber, A., Fritsche‐Guenther, R., Witzel, F., Berry, L., Schumacher, D., Yan, Y., Durek, P., Merchant, M. A., Schäfer, R., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.29 · Cited by 155
Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156
Brudvik, K. W., Mise, Y., Chung, M. H., Chun, Y. S., Kopetz, S., Passot, G., Conrad, C. H., Maru, D. M., Aloia, T. A., & Vauthey, J. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5187-2 · Cited by 151
Schmiegel, W., Scott, R. J., Dooley, S., Lewis, W., Meldrum, C. J., Pockney, P. G., Draganic, B. D., Smith, S., Hewitt, C., Phillimore, H., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12023 · Cited by 152
Troiani, T., Martinelli, E., Napolitano, S., Vitagliano, D., Ciuffreda, L. P., Costantino, S., Morgillo, F., Capasso, A., Sforza, V., Nappi, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0423 · Cited by 150
Takahashi, M., Cuatrecasas, M., Balaguer, F., Hur, K., Toiyama, Y., Castells, A., Boland, C. R., & Goel, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046684 · Cited by 153
Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers
Perkins, G., Yap, T. A., Pope, L., Mulick, A. R., Dukes, J. P., Riisnaes, R., Massard, C., Cassier, P. A., Miranda, S., Clark, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047020 · Cited by 152
RAS mutations in human cancers: Roles in precision medicine
Murugan, A. K., Grieco, M., & Tsuchida, N. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.007 · Cited by 146
Targeting the human EGFR family in esophagogastric cancer
Okines, A. F. C., Cunningham, D., & Chau, I. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.45 · Cited by 152
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
Dickler, M. N., Cobleigh, M., Miller, K. D., Klein, P. M., & Winer, E. P. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0055-9 · Cited by 146
Datta, J., Narayan, R. R., Kemeny, N. E., & D'Angelica, M. I. (2019) · JAMA Surgery · doi:10.1001/jamasurg.2019.1694 · Cited by 148
KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy
Siddiqui, A. D., & Piperdi, B. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0811-z · Cited by 148
Evaluating Many Treatments and Biomarkers in Oncology: A New Design
Kaplan, R. S., Maughan, T., Crook, A. M., Fisher, D. J., Wilson, R. H., Brown, L. C., & Parmar, M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.7905 · Cited by 141
Dietel, M., Jöhrens, K., von Laffert, M., Hummel, M., Bläker, H., Pfitzner, B. M., Lehmann, A., Denkert, C., Darb‐Esfahani, S., Lenze, D., et al. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.39 · Cited by 150
Mechanisms of resistance to HER family targeting antibodies
Kruser, T. J., & Wheeler, D. L. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.01.009 · Cited by 142
Cézé, N., Thibault, G., Goujon, G., Viguier, J., Watier, H., Dorval, E. D., & Lecomte, T. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1610-3 · Cited by 141
Integrating biomarkers in clinical trials
Buyse, M. E., Michiels, S., Sargent, D. J., Grothey, A. F., Matheson, A., & de Gramont, A. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.120 · Cited by 144
Targeting EGFR in Colorectal Cancer
Messersmith, W. A., & Ahnen, D. J. (2008) · New England Journal of Medicine · doi:10.1056/nejme0806778 · Cited by 143
Tumor heterogeneity in the clinic: is it a real problem?
Jankú, F. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834013517414 · Cited by 144
Tsongalis, G. J., Peterson, J. D., Abreu, F. B. D., Tunkey, C. D., Gallagher, T. L., Strausbaugh, L. D., Wells, W. A., & Amos, C. I. (2013) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0883 · Cited by 140
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 145
Reidy, D. L., Vakiani, E., Fakih, M. G., Saif, M. W., Hecht, J. R., Goodman-Davis, N., Hollywood, E., Shia, J., Schwartz, J., Chandrawansa, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.4154 · Cited by 138
Detection of KRAS and BRAF Mutations in Colorectal Carcinoma
Arcila, M. E., Lau, C., Nafa, K., & Ladanyi, M. (2011) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.005 · Cited by 138
Mittmann, N., Au, H., Tu, D., O'Callaghan, C. J., Isogai, P. K., Karapetis, C. S., Zalcberg, J. R., Evans, W. K., Moore, M. J., Siddiqui, J., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp232 · Cited by 139
Gollins, S., Moran, B. J., Adams, R., Cunningham, C., Bach, S. P., Myint, A. S., Renehan, A. G., Karandikar, S. S., Goh, V., Prezzi, D., et al. (2017) · Colorectal Disease · doi:10.1111/codi.13705 · Cited by 138
Microbial markers in colorectal cancer detection and/or prognosis
Villéger, R., Lopès, A., Véziant, J., Gagnière, J., Barnich, N., Billard, E., Boucher, D., & Bonnet, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i22.2327 · Cited by 146
Frattini, M., Gallino, G., Signoroni, S., Balestra, D., Lusa, L., Battaglia, L., Sozzi, G., Bertario, L., Leo, E., Pilotti, S., et al. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.021 · Cited by 136
Peeters, M., Siena, S., Cutsem, E. V., Sobrero, A. F., Hendlisz, A., Cascinu, S., Kalofonos, H. P., Devercelli, G., Wolf, M., & Amado, R. G. (2009) · Cancer · doi:10.1002/cncr.24088 · Cited by 138
Self-citationMelosky, B. L., Burkes, R. L., Rayson, D., Alcindor, T., Shear, N. H., & Lacouture, M. E. (2009) · Current Oncology · doi:10.3747/co.v16i1.361 · Cited by 136
Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.
Glassman, P. M., & Balthasar, J. P. (2014) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2014.01.002 · Cited by 141
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133
“…a strong correlation between mutated KRAS and a lack of response to cetuximab therapy indicating that KRAS status as a predictive factor (Amado et al., 2008; Bokemeyer et al., 2008; De Roock et al., 2008; Di Fiore et al., 2007; Karapetis et al., 2008; Khambata-Ford et al., 2007; Lievre…”
BackgroundBurtness, B. A., Anadkat, M. J., Basti, S., Hughes, M., Lacouture, M. E., McClure, J. S., Myskowski, P. L., Jennifer, P., Perlis, C., Saltz, L. B., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0074 · Cited by 135
Zhang, W., Winder, T., Ning, Y., Pohl, A. C., Yang, D., Kahn, M. R., Lurje, G., LaBonte, M. J., Wilson, P. M., Gordon, M. A., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq315 · Cited by 138
Trivedi, S., Srivastava, R. M., Concha‐Benavente, F., Ferrone, S., García-Bates, T. M., Li, J., & Ferris, R. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2971 · Cited by 133
Vogel, A., Hofheinz, R., Kubicka, S., & Arnold, D. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.007 · Cited by 135
Kamel, H. F. M., & Al-Amodi, H. S. A. B. (2017) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.11.005 · Cited by 137
Cathomas, G. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00035 · Cited by 133
Mutations and Response to Epidermal Growth Factor Receptor Inhibitors
Laurent‐Puig, P., Lièvre, A., & Blons, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0905 · Cited by 134
KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer
Martin, P., Leighl, N. B., Tsao, M., & Shepherd, F. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318283d958 · Cited by 135
Molecular phenotypes of colorectal cancer and potential clinical applications
Kocarnik, J., Shiovitz, S., & Phipps, A. I. (2015) · Gastroenterology report · doi:10.1093/gastro/gov046 · Cited by 133
Tian, S., Simon, I., Moreno, V., Roepman, P., Tabernero, J., Snel, M., van't Veer, L., Salazar, R., Bernards, R., & Capella, G. (2013) · Gut · doi:10.1136/gutjnl-2012-302423 · Cited by 128
Effects of systemic chemotherapy on the liver
Ramadori, G., & Cameron, S. (2010) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31651-5 · Cited by 132
Mostert, B., Jiang, Y., Sieuwerts, A. M., Wang, H., Vries, J. B., Biermann, K., Kraan, J., Lalmahomed, Z. S., van Galen, A., de Weerd, V., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27987 · Cited by 133
Calandri, M., Yamashita, S., Gazzera, C., Fonio, P., Veltri, A., Bustreo, S., Sheth, R. A., Yevich, S. M., Vauthey, J., & Odisio, B. C. (2018) · European Radiology · doi:10.1007/s00330-017-5273-2 · Cited by 130
Sun, H., Ou, B., Zhao, S., Liu, X., Song, L., Liu, X., Wang, R., & Peng, Z. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.061 · Cited by 130
The tumor microenvironment controls drug sensitivity
Östman, A. (2012) · Nature Medicine · doi:10.1038/nm.2938 · Cited by 135
Review of Histopathological and Molecular Prognostic Features in Colorectal Cancer
Marzouk, O., & Schofield, J. B. (2011) · Cancers · doi:10.3390/cancers3022767 · Cited by 143
Fu, F., Nowak, M. A., & Bonhoeffer, S. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004142 · Cited by 129
Current Targeted Therapy for Metastatic Colorectal Cancer
Ohishi, T., Kaneko, M. K., Yoshida, Y., Takashima, A., Kato, Y., & Kawada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021702 · Cited by 138
The role of the PI3K pathway in colorectal cancer
Papadatos-Pastos, D., Rabbie, R., Ross, P., & Sarker, D. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.12.006 · Cited by 126
Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion
Potthoff, K., Hofheinz, R., Hassel, J. C., Volkenandt, M., Lordick, F., Hartmann, J. T., Karthaus, M., Riess, H. B., Lipp, H., Hauschild, A., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq387 · Cited by 128
Metadata
- Authors
- Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S. D., & Chang, D. D.
- Affiliations
- Ghent University Hospital (BE)
- Amgen (United States) (US)
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca’ Granda, Milan, Italy
- Venue
- Journal of Clinical Oncology
- Published
- 2008-04-01
- Volume
- 26
- Issue
- 10
- Pages
- 1626-1634
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106789440
- Cited by
- 3,207
- References
- 38
- Citations by year
- 2026: 32 · 2025: 48 · 2024: 59 · 2023: 77 · 2022: 112 · 2021: 123 · 2020: 106 · 2019: 135 · 2018: 131 · 2017: 163 · 2016: 181 · 2015: 253 · 2014: 280 · 2013: 254 · 2012: 288
- FWCI
- 169.59
- Type
- journal article
- Language
- en
- Update notices
- new_edition (2023-06-14)
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- panitumumab, KRAS wild-type, KRAS mutation, metastatic colorectal cancer, anti-EGFR therapy, epidermal growth factor receptor, biomarker selection, progression-free survival, best supportive care, treatment toxicity, patient selection
- MeSH terms
- Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Proto-Oncogene Proteins, Biomarkers, Tumor, Colorectal Neoplasms, Polymerase Chain Reaction, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, Drug Resistance, Neoplasm, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
